Showing 1 - 3 results of 3 for search 'JA Gilbride', query time: 0.02s Refine Results
  1. 1
    PO.5.102 Pharmacokinetic modelling of belimumab in patients with lupus nephritis: intravenous and subcutaneous loading dose regimen justification

    PO.5.102 Pharmacokinetic modelling of belimumab in patients with lupus nephritis: intravenous and subcutaneous loading dose regimen justification by Y Green, I Parodis, RA Levy, JA Gilbride, L Liefaard, C Henning, R Dimelow

    Published 2022-10-01
    Article
  2. 2
    PO.5.101 The effect of belimumab on renal outcomes in a pre-specified subgroup analysis of a phase 3 randomised trial in a european population with lupus nephritis

    PO.5.101 The effect of belimumab on renal outcomes in a pre-specified subgroup analysis of a phase 3 randomised trial in a european population with lupus nephritis by L Andreoli, E Morales, Z Amoura, P Korsten, A Jones-Leone, RA Levy, JA Gilbride, H Carnarius

    Published 2022-10-01
    Article
  3. 3
    PO.5.105 The effect of belimumab on extra-renal outcomes: results from the phase 3, randomised, placebo-controlled, 104-week bliss-ln study in patients with active lupus nephritis

    PO.5.105 The effect of belimumab on extra-renal outcomes: results from the phase 3, randomised, placebo-controlled, 104-week bliss-ln study in patients with active lupus nephritis... by M Okada, J Weinmann-Menke, C Arriens, R Furie, A Jones-Leone, RA Levy, JA Gilbride, N Yang

    Published 2022-10-01
    Article

Search Tools: